Summary Anti-tumour responses with CCRG 81010, M & B 39565, NSC 353451, (Muggia, 1987) . The limited clinical activity observed amongst anti-cancer drugs is likely to be a direct result of the methods used in their selection. The most striking finding is the extent to which the activity discovered amongst the drugs is confined to the haematological malignancies. While this may represent innate sensitivity of these tumours to cytotoxic agents it may also be that the pre-clinical screening programmes of the NCI, based heavily on the murine leukaemias, select new agents active primarily in human leukaemia and lymphoma (Marsoni et al., 1987) . Furthermore a radical departure in the screening programme in the NCI is now underway but nevertheless carefully chosen transplantable mouse tumours can (and should) have their place in the new strategies being developed (Corbett et al., 1987) .
The most disappointing area of anti-cancer drug development is activity in common solid tumours which lags far behind lymphomas and leukaemias. Most of the agents which enter clinical trial have scant or no activity against solid tumours of mice (Corbett et al., 1984; . One must conclude therefore that the criteria for identifying new drugs for clinical development in the National Cancer Institute (NCI) screens for 1970 to 1985 are unsatisfactory for the detection of clinically useful drugs against the common human cancers (Muggia, 1987) . The limited clinical activity observed amongst anti-cancer drugs is likely to be a direct result of the methods used in their selection. The most striking finding is the extent to which the activity discovered amongst the drugs is confined to the haematological malignancies. While this may represent innate sensitivity of these tumours to cytotoxic agents it may also be that the pre-clinical screening programmes of the NCI, based heavily on the murine leukaemias, select new agents active primarily in human leukaemia and lymphoma (Marsoni et al., 1987) . Furthermore a radical departure in the screening programme in the NCI is now underway but nevertheless carefully chosen transplantable mouse tumours can (and should) have their place in the new strategies being developed (Corbett et al., 1987) .
Mitozolomide [CCRG 81010, M&B 39565, NSC 353451, 8-carbamoyl-3-(2-chloroethyl)imidazo [5,1 -d] -1,2,3,5-tetrazin-4(3H)-one] is a new anti-tumour agent possessing a novel chemical structure (Stevens et al., 1984) with significant activity against a wide range of murine tumours (Hickman et al., 1982) . Horgan & Tisdale (1984) proposed that the cytotoxicity of mitozolomide is mediated via its breakdown product, MCTIC (5-[3-(2-chloroethyl)triazen 1-yl]-imidazole-4-carboxamide) by the formation of interstrand cross links with DNA in a similar manner to that described for the chloroethyl nitrosoureas (Gibson et al., 1984 
Animals
Pure strain NMRI mice aged 8-10 weeks from our inbred colony were used. They were fed on CRM diet (Labsure, UK) and water ad libitum.
Tumour system
The development of several adenocarcinomata of the large bowel in NMRI mice from primary tumours induced by prolonged administration of 1,2-dimethylhydrazine has been described elsewhere . BML1 is a spontaneous lymphoma, derived in this laboratory, which has been serially passaged by intraperitoneal (i.p.) inoculation of a spleen cell suspension (1 x 106) for a period of 3 years. BML1 cells were inoculated into male mice. The poorly differentiated MAC 13 (Cowen et al., 1980) and MAC 16 The effects of mitozolomide on the bone marrow were assayed by the spleen colony forming unit method of Till & McCulloch (1961) . The mice were exposed to Xirradiation from a Newton Victor Superficial Therapy Unit (GXIO) at a dose of 11.7Gy. They were subsequently injected i.v. via the tail vein with 1 x 105 marrow cells either from control mice or from mice which had been treated 24 h previously with mitozolomide. Eight days later the mice were killed, the spleens removed and fixed in Bouin's fluid and the nodules which can readily be seen on the spleen were counted. (Wahed et al., 1987) and MeCCNU has a similar mechanism of action to mitozolomide. The testes were removed and weighed, either fixed with Bouin's fluid and then subjected to routine histological processing, or placed in distilled water, homogenised and sonicated for sperm head counts (Meistrich et al., 1978) . Haemopoietic toxicity 1. Peripheral blood counts: Single i.p. injection of mitozolomide at maximum tolerated dose had no effect on peripheral blood erythrocyte count (Figure la) . Leucocyte counts were depleted on day 4 (P<0.01) ( Figure  lb) . Platelet counts were significantly depressed (P<0.01) on days 7, 11 and 14 (Figure lc ). 2. Spleen colony forming unit (CFU-S assay): The effects of mitozolomide on CFU-S are described in Table II . Figure 2 . There was a significant decrease in testicular weight following treatment at maximum tolerated dose with both mitozolomide and thioTEPA. MeCCNU had no significant effect on testis weight. Examination of tissue sections revealed a significant decrease (P<0.01) in the diameter of seminiferous tubules in mice treated with mitozolomide and thioTEPA at 22 and 32 days after injection (Figure 3 ). These changes were accompanied by a depletion in spermatogonia, spermatocytes and early spermatids resulting in a decrease in germinal epithelial size (Figure 4) . No significant changes in these parameters were seen following MeCCNU treatment. Sperm head counts revealed a significant depression (P<0.01) following mitozolomide and thioTEPA treatment ( Figure 5 ). MeCCNU did not produce a significant depression in sperm head count. Following inoculation of 1.2 x 105 bone marrow cells in normal irradiated mice, 40 colonies were seen in the spleen. Treatment of donor mice with a dose of 40 mg kg-1 mitozolomide resulted in complete destruction of CFU-S in recipient mice. Lower doses of mitozolomide resulted in approximately a 10-fold reduction in CFU-S compared to control mice. (Connors, 1985) . In pre-clinical toxicity studies organ specific toxicity is only determined retrospectively should any untoward clinical symptoms appear (Fox, personal communication 
